InnoCare Pharma Revenue and Competitors
Estimated Revenue & Valuation
- InnoCare Pharma's estimated annual revenue is currently $4.2M per year.
- InnoCare Pharma's estimated revenue per employee is $77,500
Employee Data
- InnoCare Pharma has 54 Employees.
InnoCare Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Chemistry | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Project Specialist | Reveal Email/Phone |
InnoCare Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $10.2M | 131 | -2% | $312.8M | N/A |
#2 | $4.2M | 54 | N/A | N/A | N/A |
#3 | $2.2M | 57 | -28% | $179.7M | N/A |
#4 | $23.9M | 309 | -14% | N/A | N/A |
#5 | $0.9M | 12 | 0% | N/A | N/A |
#6 | $1.7M | 22 | 0% | N/A | N/A |
#7 | $19M | 245 | -14% | N/A | N/A |
#8 | $9.4M | 121 | 3% | N/A | N/A |
What Is InnoCare Pharma?
N/A
Total Funding
54
Number of Employees
$4.2M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
InnoCare Pharma News
InnoCare Pharma Ltd (9969.HK) - Lack of Clear Commercialization Prospects. Equity Bottom-Up. 99 Views, 26 Apr 2022 08:38. EXECUTIVE SUMMARY.
InnoCare Pharma Ltd (9969.HK) Lack of Clear Commercialization Prospects; Rainbow Children's Hospital IPO Thoughts on Valuation. Rainbow...
InnoCare Pharma's A-share IPO will make it the fourth innovative pharma company with shares traded in Hong Kong and on the mainland's STAR...
BEIJING--(BUSINESS WIRE)--Feb 28, 2021-- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Dr. Sean Zhang as Chief Medical Officer (CMO). Reporting to the Co-founder, Chairwoman and CEO, Dr. ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.2M | 54 | 10% | N/A |
#2 | $12.2M | 54 | 2% | N/A |
#3 | $8.7M | 54 | 6% | N/A |
#4 | $11.9M | 54 | 4% | N/A |
#5 | $15.8M | 54 | 4% | N/A |